Curis SEC Filings

Curis, Inc. (CRIS) filed a Form S-8 to register 1,255,000 shares of common stock for issuance under its Fifth Amended and Restated 2010 Stock Incentive Plan, as amended, and 84,750 shares issuable pursuant to inducement stock option awards granted during May 1, 2025 through October 1, 2025.

The filing incorporates by reference the company’s most recent Annual Report, Quarterly Reports, and specified Current Reports. This registration supports equity compensation and hiring tools by making additional shares available under the plan and the disclosed inducement awards.

Curis, Inc. filed its Q3 2025 10-Q reporting continued operating losses and tight liquidity. Net revenues were $3.176 million for the quarter, with a net loss of $7.729 million and net loss per share of $0.49. For the nine months, net revenues were $8.305 million and net loss totaled $26.938 million.

Cash and cash equivalents were $9.051 million as of September 30, 2025, and management disclosed conditions that raise substantial doubt about the company’s ability to continue as a going concern. Operating cash use was $20.830 million for the nine months.

Curis completed financings in March 2025 and July 2025, issuing common stock, pre‑funded warrants, and common warrants, with combined net proceeds of approximately $14.9 million. Total liabilities were $42.332 million, including $28.631 million related to the sale of future Erivedge royalties.

Subsequent event: on November 6, 2025, Curis sold its interest in Curis Royalty LLC to an Oberland affiliate for $2.5 million and obtained a release of the royalty‑related liability; Curis will no longer receive Erivedge collaboration revenues and expects to record a gain in Q4 2025.

Curis, Inc. (CRIS) completed the sale of its Erivedge business—including its interest in Curis Royalty LLC, Erivedge intellectual property, and its rights under the Genentech license—in exchange for $2.5 million upfront and a release of the company’s liability related to the prior sale of future royalties to Oberland.

The company transferred all related technology and assigned its rights and obligations under the license to Curis Royalty. Curis expects to recognize a gain in Q4 2025 and the liability tied to sold future royalties will be extinguished. Following the sale, Curis will no longer receive revenue under the Erivedge license.

Separately, Nasdaq granted an exception until November 14, 2025 to regain compliance with the market value of listed securities rule. Curis believes, as of this report, that its stockholders’ equity is well above the $2.5 million alternative threshold under Listing Rule 5550(b)(1), though the Panel’s decision is not assured.

Curis, Inc. reported that Nasdaq’s Hearings Panel granted an exception until November 14, 2025 to regain compliance with the Nasdaq Listing Rule 5550(b)(2) market value of listed securities requirement of $35,000,000.

During this period, the company must promptly notify Nasdaq of any significant events affecting compliance, and the Panel may reconsider the exception if circumstances change. The notice states there is no assurance the company will regain compliance or remain listed on Nasdaq.

Curis, Inc. received a delisting notice from Nasdaq after failing to meet the minimum market value of listed securities ($35,000,000) for 30 consecutive trading days. Nasdaq gave a 180‑day compliance period that expired on August 20, 2025, and on August 21, 2025 the Listing Qualifications Staff notified the company that its securities would be delisted unless the company requests a hearing by August 28, 2025. The company intends to request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting while the appeal is pending. The common stock remains listed and tradable on Nasdaq during the appeal, but there is no assurance the company will regain compliance.

Armistice Capital and Steven Boyd report beneficial ownership of 1,287,337 shares of Curis Inc (CUSIP 00510M203), representing 9.99% of the company's common stock. Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and exercises shared voting and dispositive power over those securities. Steven Boyd, as managing member of Armistice Capital, is reported with the same shared voting and dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of influencing control.

M28 Capital Management LP and Marc Elia report beneficial ownership of 620,167 shares of Curis common stock, representing 5.9% of the outstanding class when assuming exercise of reported warrants. The reported stake includes 99,108 shares issuable upon exercise of warrants, and the percentage is calculated using an aggregate share base of 10,561,358 shares.

The filing shows the reporting persons possess only shared voting and dispositive power over these shares, and it certifies the holdings were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control.

Curis, Inc. filed a prospectus supplement under its existing shelf registration to offer and sell up to $8,137,047 of its common stock through an Amended and Restated Sales Agreement with Cantor Fitzgerald & Co. and JonesTrading Institutional Services LLC acting as agents. The Shares are registered under the companys Registration Statement and will be offered only by means of the Prospectus Supplement.

The company notified the agents that it terminated a prior prospectus related to an offering of up to $100.0 million, while confirming the Sales Agreement remains in full force and effect. Wilmer Cutler Pickering Hale and Dorr LLP provided a legal opinion and consent included as exhibits. This filing documents terms for a potential equity offering and the related legal opinions; it does not itself constitute a sale of securities.

Curis, Inc. filed a prospectus supplement dated August 8, 2025 registering an at-the-market (ATM) program to sell up to $8,137,047 of common stock through Cantor Fitzgerald & Co. and JonesTrading as sales agents, who will receive a 3% commission on gross sales. The offering is being made under an amended sales agreement and the shares may be sold from time to time at market prices.

The company focuses on emavusertib (CA-4948), an orally available IRAK4 inhibitor licensed via a 2015 collaboration with Aurigene, and has licensed Erivedge rights to Genentech. As of June 30, 2025 Curis had $10.1 million in cash and cash equivalents and completed July 2025 offerings that generated approximately $6.0 million net proceeds. Management states that existing cash plus July proceeds should fund operations into the first quarter of 2026, but the company discloses substantial doubt about its ability to continue as a going concern beyond 12 months. Curis also faces a Nasdaq market-value deficiency and must regain a $35 million market value by August 20, 2025 to avoid delisting.